Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1.
Sala-Rabanal M
,
Loo DD
,
Hirayama BA
,
Turk E
,
Wright EM
.
???displayArticle.abstract???
The human intestinal proton-coupled oligopeptide transporter hPEPT1 has been implicated in the absorption of pharmacologically active compounds. We have investigated the interactions between a comprehensive selection of drugs, and wild-type and variant hPEPT1s expressed in Xenopus oocytes, using radiotracer uptake and electrophysiological methods. The beta-lactam antibiotics ampicillin, amoxicillin, cephalexin and cefadroxil, the antineoplastics delta-aminolevulinic acid (delta-ALA) and bestatin, and the neuropeptide N-acetyl-Asp-Glu (NAAG), were transported, as judged by their ability to evoke inward currents. When the drugs were added in the presence of the typical substrate glycylsarcosine (Gly-Sar), the inward currents were equal or less than that induced by Gly-Sar alone. This suggests that the drugs are transported at a lower turnover rate than Gly-Sar, but may also point towards complex interactions between dipeptides, drugs and the transporter. Gly-Sar and the drugs also modified the kinetics of hPEPT1 presteady-state charge movement, by causing a reduction in maximum charge (Qmax) and a shift of the midpoint voltage (V0.5) to more negative potentials. Our results indicate that the substrate selectivity of hPEPT1 is: Gly-Sar > NAAG, delta-ALA, bestatin > cefadroxil, cephalexin > ampicillin, amoxicillin. Based on steady-state and presteady-state analysis of Gly-Sar and cefadroxil transport, we proposed an extension of the 6-state kinetic model for hPEPT1 function that globally accounts for the observed presteady-state and steady-state kinetics of neutral dipeptide and drug transport. Our model suggests that, under saturating conditions, the rate-limiting step of the hPEPT1 transport cycle is the reorientation of the empty carrier within the membrane. Variations in rates of drug cotransport are predicted to be due to differences in affinity and turnover rate. Oral availability of drugs may be reduced in the presence of physiological concentrations of dietary dipeptides in the gut, suggesting that oral delivery drugs should be taken on an empty stomach. The common hPEPT1 single-nucleotide polymorphisms Ser117Asn and Gly419Ala retained the essential kinetic and drug recognition characteristics of the wild type, suggesting that neither variant is likely to have a major impact on oral absorption of drugs.
Anderle,
Genetic variants of the human dipeptide transporter PEPT1.
2006, Pubmed
Anderle,
Genetic variants of the human dipeptide transporter PEPT1.
2006,
Pubmed
Boll,
Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, beta-lactam antibiotics and ACE-inhibitors.
1994,
Pubmed
,
Xenbase
Boorer,
Steady-state and presteady-state kinetics of the H+/hexose cotransporter (STP1) from Arabidopsis thaliana expressed in Xenopus oocytes.
1994,
Pubmed
,
Xenbase
Bretschneider,
Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux.
1999,
Pubmed
Daniel,
The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology.
2004,
Pubmed
Daniel,
Molecular and integrative physiology of intestinal peptide transport.
2004,
Pubmed
Diez-Sampedro,
A glucose sensor hiding in a family of transporters.
2003,
Pubmed
,
Xenbase
Döring,
Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications.
1998,
Pubmed
,
Xenbase
Eskandari,
Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity.
1997,
Pubmed
,
Xenbase
Fei,
Expression cloning of a mammalian proton-coupled oligopeptide transporter.
1994,
Pubmed
,
Xenbase
Forster,
Stoichiometry and Na+ binding cooperativity of rat and flounder renal type II Na+-Pi cotransporters.
1999,
Pubmed
,
Xenbase
Ganapathy,
Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.
1998,
Pubmed
Ganapathy,
Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2.
1995,
Pubmed
Ganapathy,
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
1997,
Pubmed
,
Xenbase
Hediger,
Expression of size-selected mRNA encoding the intestinal Na/glucose cotransporter in Xenopus laevis oocytes.
1987,
Pubmed
,
Xenbase
Hu,
Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa.
1989,
Pubmed
Inui,
H+ coupled active transport of bestatin via the dipeptide transport system in rabbit intestinal brush-border membranes.
1992,
Pubmed
Irie,
Computational modelling of H+-coupled peptide transport via human PEPT1.
2005,
Pubmed
Kottra,
Bidirectional electrogenic transport of peptides by the proton-coupled carrier PEPT1 in Xenopus laevis oocytes: its asymmetry and symmetry.
2001,
Pubmed
,
Xenbase
Liang,
Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization.
1995,
Pubmed
,
Xenbase
Loo,
Role of Cl- in electrogenic Na+-coupled cotransporters GAT1 and SGLT1.
2000,
Pubmed
,
Xenbase
Loo,
Relaxation kinetics of the Na+/glucose cotransporter.
1993,
Pubmed
,
Xenbase
Loo,
Conformational changes couple Na+ and glucose transport.
1998,
Pubmed
,
Xenbase
Mackenzie,
Relationships between Na+/glucose cotransporter (SGLT1) currents and fluxes.
1998,
Pubmed
,
Xenbase
Mackenzie,
Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2.
1996,
Pubmed
,
Xenbase
Mackenzie,
Mechanisms of the human intestinal H+-coupled oligopeptide transporter hPEPT1.
1996,
Pubmed
,
Xenbase
Parent,
Electrogenic properties of the cloned Na+/glucose cotransporter: II. A transport model under nonrapid equilibrium conditions.
1992,
Pubmed
Parent,
Electrogenic properties of the cloned Na+/glucose cotransporter: I. Voltage-clamp studies.
1992,
Pubmed
,
Xenbase
Rubio-Aliaga,
Mammalian peptide transporters as targets for drug delivery.
2002,
Pubmed
Sadee's,
Pharmacogenomics. Interview by Clare Thompson.
2000,
Pubmed
Soragna,
Relations between substrate affinities and charge equilibration rates in the rat GABA cotransporter GAT1.
2005,
Pubmed
,
Xenbase
Temple,
Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter.
1998,
Pubmed
,
Xenbase
Terada,
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
1997,
Pubmed
Terada,
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
2000,
Pubmed
Wang,
Electrophysiological characteristics of the proton-coupled peptide transporter PEPT2 cloned from rat brain.
1998,
Pubmed
,
Xenbase
Wenzel,
Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.
1996,
Pubmed
,
Xenbase
Yamashita,
Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters.
2005,
Pubmed
Zhang,
Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1: implications for the functional role of Pro586.
2004,
Pubmed
Zhu,
Differential recognition of ACE inhibitors in Xenopus laevis oocytes expressing rat PEPT1 and PEPT2.
2000,
Pubmed
,
Xenbase